APO Research
Talk to an analyst

APO RESEARCH · REPORT

Oral Hypoglycemic Agents (OHAs)

Compare research editions
View pricing & licenses

Selected research

Market Structure

Global Oral Hypoglycemic Agents (OHAs) Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032

20 December 2025198 pages

Choose your research edition.

Industry ResearchOral Hypoglycemic Agents (OHAs) Industry Research Report 2026120 pages · $2,950 USDIndustry Growth & TrendsGlobal Oral Hypoglycemic Agents (OHAs) Industry Growth and Trends Forecast to 2032100 pages · $3,450 USDMarket StructureGlobal Oral Hypoglycemic Agents (OHAs) Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032198 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Oral Hypoglycemic Agents (OHAs) Market Outlook and Growth Opportunities 2026198 pages · $4,250 USDMarket Analysis & ForecastGlobal Oral Hypoglycemic Agents (OHAs) Market Analysis and Forecast 2026-2032190 pages · $4,950 USD

Market perspective

The global Oral Hypoglycemic Agents (OHAs) market is projected to grow from US$ million in 2026 to US$ million by 2032, implying a CAGR of % over 2026-2032.

The US & Canada market for Oral Hypoglycemic Agents (OHAs) is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Oral Hypoglycemic Agents (OHAs) is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Oral Hypoglycemic Agents (OHAs) is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The China market for Oral Hypoglycemic Agents (OHAs) is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Leading global manufacturers of Oral Hypoglycemic Agents (OHAs) include Bristol-Myers Squibb, Double-Crane Pharmaceutical, Novonordisk, Sanofi-Aventis, Servier, Bayer, Wanbang Biopharmaceuticals, GlaxoSmithKline and Guangzhou Pharmaceutical, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Oral Hypoglycemic Agents (OHAs) market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Oral Hypoglycemic Agents (OHAs) and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Oral Hypoglycemic Agents (OHAs) sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Oral Hypoglycemic Agents (OHAs) market size, projected growth trends, production technologies, key applications, and end-use industries.

Oral Hypoglycemic Agents (OHAs) Segment by Company

Bristol-Myers Squibb

Double-Crane Pharmaceutical

Novonordisk

Sanofi-Aventis

Servier

Bayer

Wanbang Biopharmaceuticals

GlaxoSmithKline

Guangzhou Pharmaceutical

Huadong Medicine

Pfizer

Oral Hypoglycemic Agents (OHAs) Segment by Type

Alpha-Glucosidase Inhibitors

Metformin

Sulfonylureas

Thiazolidinediones

Oral Hypoglycemic Agents (OHAs) Segment by Application

Type 2 Diabetes Mellitus

Type 1 Diabetes Mellitus

Oral Hypoglycemic Agents (OHAs) Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

UAE

Study Objectives

1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Oral Hypoglycemic Agents (OHAs) market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Oral Hypoglycemic Agents (OHAs) and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Oral Hypoglycemic Agents (OHAs).

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Oral Hypoglycemic Agents (OHAs) market, including product definition, global market growth prospects, market size, sales, and average price forecasts (2021-2032).

Chapter 2: Provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Detailed analysis of Oral Hypoglycemic Agents (OHAs) manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales of Oral Hypoglycemic Agents (OHAs) in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 7: Revenue of Oral Hypoglycemic Agents (OHAs) in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights of the report

More report detail

Tables and figures
List of Tables Table 1. Oral Hypoglycemic Agents (OHAs) Industry Trends Table 2. Oral Hypoglycemic Agents (OHAs) Industry Drivers Table 3. Oral Hypoglycemic Agents (OHAs) Industry Opportunities and Challenges Table 4. Oral Hypoglycemic Agents (OHAs) Industry Restraints Table 5. Global Oral Hypoglycemic Agents (OHAs) Revenue by Manufacturers (US$ Million) & (2021-2026) Table 6. Global Oral Hypoglycemic Agents (OHAs) Revenue Market Share by Manufacturers (2021-2026) Table 7. Global Oral Hypoglycemic Agents (OHAs) Sales by Manufacturers (K Units) & (2021-2026) Table 8. Global Oral Hypoglycemic Agents (OHAs) Sales Market Share by Manufacturers Table 9. Global Oral Hypoglycemic Agents (OHAs) Average Sales Price (US$/Unit) of Manufacturers (2021-2026) Table 10. Global Oral Hypoglycemic Agents (OHAs) Industry Manufacturers Ranking, 2024 VS 2025 VS 2026 Table 11. Global Oral Hypoglycemic Agents (OHAs) Key Manufacturers Manufacturing Sites & Headquarters Table 12. Global Oral Hypoglycemic Agents (OHAs) Manufacturers, Product Type & Application Table 13. Global Oral Hypoglycemic Agents (OHAs) Manufacturers Establishment Date Table 14. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 15. Global Oral Hypoglycemic Agents (OHAs) by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue of 2025) Table 16. Major Manufacturers of Alpha-Glucosidase Inhibitors Table 17. Major Manufacturers of Metformin Table 18. Major Manufacturers of Sulfonylureas Table 19. Major Manufacturers of Thiazolidinediones Table 20. Global Oral Hypoglycemic Agents (OHAs) Sales by Type 2021 VS 2025 VS 2032 (K Units) Table 21. Global Oral Hypoglycemic Agents (OHAs) Sales by Type (2021-2026) & (K Units) Table 22. Global Oral Hypoglycemic Agents (OHAs) Sales by Type (2027-2032) & (K Units) Table 23. Global Oral Hypoglycemic Agents (OHAs) Sales Market Share by Type (2021-2026) Table 24. Global Oral Hypoglycemic Agents (OHAs) Sales Market Share by Type (2027-2032) Table 25. Global Oral Hypoglycemic Agents (OHAs) Revenue by Type 2021 VS 2025 VS 2032 (K Units) Table 26. Global Oral Hypoglycemic Agents (OHAs) Revenue by Type (2021-2026) & (K Units) Table 27. Global Oral Hypoglycemic Agents (OHAs) Revenue by Type (2027-2032) & (K Units) Table 28. Global Oral Hypoglycemic Agents (OHAs) Revenue Market Share by Type (2021-2026) Table 29. Global Oral Hypoglycemic Agents (OHAs) Revenue Market Share by Type (2027-2032) Table 30. Major Manufacturers of Type 2 Diabetes Mellitus Table 31. Major Manufacturers of Type 1 Diabetes Mellitus Table 32. Global Oral Hypoglycemic Agents (OHAs) Sales by Application 2021 VS 2025 VS 2032 (K Units) Table 33. Global Oral Hypoglycemic Agents (OHAs) Sales by Application (2021-2026) & (K Units) Table 34. Global Oral Hypoglycemic Agents (OHAs) Sales by Application (2027-2032) & (K Units) Table 35. Global Oral Hypoglycemic Agents (OHAs) Sales Market Share by Application (2021-2026) Table 36. Global Oral Hypoglycemic Agents (OHAs) Sales Market Share by Application (2027-2032) Table 37. Global Oral Hypoglycemic Agents (OHAs) Revenue by Application 2021 VS 2025 VS 2032 (K Units) Table 38. Global Oral Hypoglycemic Agents (OHAs) Revenue by Application (2021-2026) & (K Units) Table 39. Global Oral Hypoglycemic Agents (OHAs) Revenue by Application (2027-2032) & (K Units) Table 40. Global Oral Hypoglycemic Agents (OHAs) Revenue Market Share by Application (2021-2026) Table 41. Global Oral Hypoglycemic Agents (OHAs) Revenue Market Share by Application (2027-2032) Table 42. Global Oral Hypoglycemic Agents (OHAs) Sales by Region: 2021 VS 2025 VS 2032 (K Units) Table 43. Global Oral Hypoglycemic Agents (OHAs) Sales by Region (2021-2026) & (K Units) Table 44. Global Oral Hypoglycemic Agents (OHAs) Sales Market Share by Region (2021-2026) Table 45. Global Oral Hypoglycemic Agents (OHAs) Sales Forecasted by Region (2027-2032) & (K Units) Table 46. Global Oral Hypoglycemic Agents (OHAs) Sales Forecasted Market Share by Region (2027-2032) Table 47. North America Oral Hypoglycemic Agents (OHAs) Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 48. North America Oral Hypoglycemic Agents (OHAs) Sales by Country (2021-2026) & (K Units) Table 49. North America Oral Hypoglycemic Agents (OHAs) Sales by Country (2027-2032) & (K Units) Table 50. Europe Oral Hypoglycemic Agents (OHAs) Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 51. Europe Oral Hypoglycemic Agents (OHAs) Sales by Country (2021-2026) & (K Units) Table 52. Europe Oral Hypoglycemic Agents (OHAs) Sales by Country (2027-2032) & (K Units) Table 53. Asia Pacific Oral Hypoglycemic Agents (OHAs) Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 54. Asia Pacific Oral Hypoglycemic Agents (OHAs) Sales by Country (2021-2026) & (K Units) Table 55. Asia Pacific Oral Hypoglycemic Agents (OHAs) Sales by Country (2027-2032) & (K Units) Table 56. South America, Middle East and Africa Oral Hypoglycemic Agents (OHAs) Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 57. South America, Middle East and Africa Oral Hypoglycemic Agents (OHAs) Sales by Country (2021-2026) & (K Units) Table 58. South America, Middle East and Africa Oral Hypoglycemic Agents (OHAs) Sales by Country (2027-2032) & (K Units) Table 59. Global Oral Hypoglycemic Agents (OHAs) Revenue Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 60. Global Oral Hypoglycemic Agents (OHAs) Revenue by Region (2021-2026) & (US$ Million) Table 61. Global Oral Hypoglycemic Agents (OHAs) Revenue by Region (2027-2032) & (US$ Million) Table 62. Global Oral Hypoglycemic Agents (OHAs) Revenue Market Share by Region (2021-2026) Table 63. Global Oral Hypoglycemic Agents (OHAs) Revenue Market Share by Region (2027-2032) Table 64. Bristol-Myers Squibb Company Information Table 65. Bristol-Myers Squibb Business Overview Table 66. Bristol-Myers Squibb Oral Hypoglycemic Agents (OHAs) Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 67. Bristol-Myers Squibb Oral Hypoglycemic Agents (OHAs) Product Portfolio Table 68. Bristol-Myers Squibb Recent Development Table 69. Double-Crane Pharmaceutical Company Information Table 70. Double-Crane Pharmaceutical Business Overview Table 71. Double-Crane Pharmaceutical Oral Hypoglycemic Agents (OHAs) Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 72. Double-Crane Pharmaceutical Oral Hypoglycemic Agents (OHAs) Product Portfolio Table 73. Double-Crane Pharmaceutical Recent Development Table 74. Novonordisk Company Information Table 75. Novonordisk Business Overview Table 76. Novonordisk Oral Hypoglycemic Agents (OHAs) Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 77. Novonordisk Oral Hypoglycemic Agents (OHAs) Product Portfolio Table 78. Novonordisk Recent Development Table 79. Sanofi-Aventis Company Information Table 80. Sanofi-Aventis Business Overview Table 81. Sanofi-Aventis Oral Hypoglycemic Agents (OHAs) Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 82. Sanofi-Aventis Oral Hypoglycemic Agents (OHAs) Product Portfolio Table 83. Sanofi-Aventis Recent Development Table 84. Servier Company Information Table 85. Servier Business Overview Table 86. Servier Oral Hypoglycemic Agents (OHAs) Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 87. Servier Oral Hypoglycemic Agents (OHAs) Product Portfolio Table 88. Servier Recent Development Table 89. Bayer Company Information Table 90. Bayer Business Overview Table 91. Bayer Oral Hypoglycemic Agents (OHAs) Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 92. Bayer Oral Hypoglycemic Agents (OHAs) Product Portfolio Table 93. Bayer Recent Development Table 94. Wanbang Biopharmaceuticals Company Information Table 95. Wanbang Biopharmaceuticals Business Overview Table 96. Wanbang Biopharmaceuticals Oral Hypoglycemic Agents (OHAs) Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 97. Wanbang Biopharmaceuticals Oral Hypoglycemic Agents (OHAs) Product Portfolio Table 98. Wanbang Biopharmaceuticals Recent Development Table 99. GlaxoSmithKline Company Information Table 100. GlaxoSmithKline Business Overview Table 101. GlaxoSmithKline Oral Hypoglycemic Agents (OHAs) Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 102. GlaxoSmithKline Oral Hypoglycemic Agents (OHAs) Product Portfolio Table 103. GlaxoSmithKline Recent Development Table 104. Guangzhou Pharmaceutical Company Information Table 105. Guangzhou Pharmaceutical Business Overview Table 106. Guangzhou Pharmaceutical Oral Hypoglycemic Agents (OHAs) Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 107. Guangzhou Pharmaceutical Oral Hypoglycemic Agents (OHAs) Product Portfolio Table 108. Guangzhou Pharmaceutical Recent Development Table 109. Huadong Medicine Company Information Table 110. Huadong Medicine Business Overview Table 111. Huadong Medicine Oral Hypoglycemic Agents (OHAs) Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 112. Huadong Medicine Oral Hypoglycemic Agents (OHAs) Product Portfolio Table 113. Huadong Medicine Recent Development Table 114. Pfizer Company Information Table 115. Pfizer Business Overview Table 116. Pfizer Oral Hypoglycemic Agents (OHAs) Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 117. Pfizer Oral Hypoglycemic Agents (OHAs) Product Portfolio Table 118. Pfizer Recent Development Table 119. Key Raw Materials Table 120. Raw Materials Key Suppliers Table 121. Oral Hypoglycemic Agents (OHAs) Distributors List Table 122. Oral Hypoglycemic Agents (OHAs) Customers List Table 123. Research Programs/Design for This Report Table 124. Authors List of This Report Table 125. Secondary Sources Table 126. Primary Sources List of Figures Figure 1. Oral Hypoglycemic Agents (OHAs) Product Image Figure 2. Global Oral Hypoglycemic Agents (OHAs) Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Oral Hypoglycemic Agents (OHAs) Market Size (2021-2032) & (US$ Million) Figure 4. Global Oral Hypoglycemic Agents (OHAs) Sales (2021-2032) & (K Units) Figure 5. Global Oral Hypoglycemic Agents (OHAs) Average Price (US$/Unit) & (2021-2032) Figure 6. Global Top 5 and 10 Oral Hypoglycemic Agents (OHAs) Players Market Share by Revenue in 2025 Figure 7. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 8. Alpha-Glucosidase Inhibitors Image Figure 9. Metformin Image Figure 10. Sulfonylureas Image Figure 11. Thiazolidinediones Image Figure 12. Global Oral Hypoglycemic Agents (OHAs) Sales by Type (2021 VS 2025 VS 2032) & (K Units) Figure 13. Global Oral Hypoglycemic Agents (OHAs) Sales Market Share 2021 VS 2025 VS 2032 Figure 14. Global Oral Hypoglycemic Agents (OHAs) Sales Market Share by Type (2021-2032) Figure 15. Global Oral Hypoglycemic Agents (OHAs) Revenue by Type (2021 VS 2025 VS 2032) & (K Units) Figure 16. Global Oral Hypoglycemic Agents (OHAs) Revenue Market Share 2021 VS 2025 VS 2032 Figure 17. Global Oral Hypoglycemic Agents (OHAs) Revenue Market Share by Type (2021-2032) Figure 18. Type 2 Diabetes Mellitus Image Figure 19. Type 1 Diabetes Mellitus Image Figure 20. Global Oral Hypoglycemic Agents (OHAs) Sales by Application (2021 VS 2025 VS 2032) & (K Units) Figure 21. Global Oral Hypoglycemic Agents (OHAs) Sales Market Share 2021 VS 2025 VS 2032 Figure 22. Global Oral Hypoglycemic Agents (OHAs) Sales Market Share by Application (2021-2032) Figure 23. Global Oral Hypoglycemic Agents (OHAs) Revenue by Application (2021 VS 2025 VS 2032) & (K Units) Figure 24. Global Oral Hypoglycemic Agents (OHAs) Revenue Market Share 2021 VS 2025 VS 2032 Figure 25. Global Oral Hypoglycemic Agents (OHAs) Revenue Market Share by Application (2021-2032) Figure 26. North America Oral Hypoglycemic Agents (OHAs) Sales and Growth Rate (2021-2032) & (K Units) Figure 27. North America Oral Hypoglycemic Agents (OHAs) Sales Market Share by Country (2021-2032) Figure 28. U.S. Oral Hypoglycemic Agents (OHAs) Sales and Growth Rate (2021-2032) & (K Units) Figure 29. Canada Oral Hypoglycemic Agents (OHAs) Sales and Growth Rate (2021-2032) & (K Units) Figure 30. Mexico Oral Hypoglycemic Agents (OHAs) Sales and Growth Rate (2021-2032) & (K Units) Figure 31. Europe Oral Hypoglycemic Agents (OHAs) Sales and Growth Rate (2021-2032) & (K Units) Figure 32. Europe Oral Hypoglycemic Agents (OHAs) Sales Market Share by Country (2021-2032) Figure 33. Germany Oral Hypoglycemic Agents (OHAs) Sales and Growth Rate (2021-2032) & (K Units) Figure 34. France Oral Hypoglycemic Agents (OHAs) Sales and Growth Rate (2021-2032) & (K Units) Figure 35. U.K. Oral Hypoglycemic Agents (OHAs) Sales and Growth Rate (2021-2032) & (K Units) Figure 36. Italy Oral Hypoglycemic Agents (OHAs) Sales and Growth Rate (2021-2032) & (K Units) Figure 37. Netherlands Oral Hypoglycemic Agents (OHAs) Sales and Growth Rate (2021-2032) & (K Units) Figure 38. Asia Pacific Oral Hypoglycemic Agents (OHAs) Sales and Growth Rate (2021-2032) & (K Units) Figure 39. Asia Pacific Oral Hypoglycemic Agents (OHAs) Sales Market Share by Country (2021-2032) Figure 40. China Oral Hypoglycemic Agents (OHAs) Sales and Growth Rate (2021-2032) & (K Units) Figure 41. Japan Oral Hypoglycemic Agents (OHAs) Sales and Growth Rate (2021-2032) & (K Units) Figure 42. South Korea Oral Hypoglycemic Agents (OHAs) Sales and Growth Rate (2021-2032) & (K Units) Figure 43. Southeast Asia Oral Hypoglycemic Agents (OHAs) Sales and Growth Rate (2021-2032) & (K Units) Figure 44. India Oral Hypoglycemic Agents (OHAs) Sales and Growth Rate (2021-2032) & (K Units) Figure 45. Australia Oral Hypoglycemic Agents (OHAs) Sales and Growth Rate (2021-2032) & (K Units) Figure 46. South America, Middle East and Africa Oral Hypoglycemic Agents (OHAs) Sales and Growth Rate (2021-2032) & (K Units) Figure 47. South America, Middle East and Africa Oral Hypoglycemic Agents (OHAs) Sales Market Share by Country (2021-2032) Figure 48. Brazil Oral Hypoglycemic Agents (OHAs) Sales and Growth Rate (2021-2032) & (K Units) Figure 49. South Africa Oral Hypoglycemic Agents (OHAs) Sales and Growth Rate (2021-2032) & (K Units) Figure 50. Saudi Arabia Oral Hypoglycemic Agents (OHAs) Sales and Growth Rate (2021-2032) & (K Units) Figure 51. Turkey Oral Hypoglycemic Agents (OHAs) Sales and Growth Rate (2021-2032) & (K Units) Figure 52. Argentina Oral Hypoglycemic Agents (OHAs) Sales and Growth Rate (2021-2032) & (K Units) Figure 53. UAE Oral Hypoglycemic Agents (OHAs) Sales and Growth Rate (2021-2032) & (K Units) Figure 54. Egypt Oral Hypoglycemic Agents (OHAs) Sales and Growth Rate (2021-2032) & (K Units) Figure 55. Chile Oral Hypoglycemic Agents (OHAs) Sales and Growth Rate (2021-2032) & (K Units) Figure 56. Global Oral Hypoglycemic Agents (OHAs) Revenue (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 57. Global Oral Hypoglycemic Agents (OHAs) Revenue Market Share by Region in Percentage: 2025 Versus 2032 Figure 58. North America Oral Hypoglycemic Agents (OHAs) Revenue (2021-2032) & (US$ Million) Figure 59. North America Oral Hypoglycemic Agents (OHAs) Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 60. Europe Oral Hypoglycemic Agents (OHAs) Revenue (2021-2032) & (US$ Million) Figure 61. Europe Oral Hypoglycemic Agents (OHAs) Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 62. Asia-Pacific Oral Hypoglycemic Agents (OHAs) Revenue (2021-2032) & (US$ Million) Figure 63. Asia-Pacific Oral Hypoglycemic Agents (OHAs) Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 64. South America, Middle East and Africa Oral Hypoglycemic Agents (OHAs) Revenue (2021-2032) & (US$ Million) Figure 65. South America, Middle East and Africa Oral Hypoglycemic Agents (OHAs) Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 66. Oral Hypoglycemic Agents (OHAs) Value Chain Figure 67. Manufacturing Cost Structure Figure 68. Oral Hypoglycemic Agents (OHAs) Production Mode & Process Figure 69. Direct Comparison with Distribution Share Figure 70. Distributors Profiles Figure 71. Years Considered Figure 72. Research Process Figure 73. Key Executives Interviewed

Scope & coverage.

Types
  • Alpha-Glucosidase Inhibitors
  • Metformin
  • Sulfonylureas
  • Thiazolidinediones
Applications
  • Type 2 Diabetes Mellitus
  • Type 1 Diabetes Mellitus
Companies covered
  • Bristol-Myers Squibb
  • Double-Crane Pharmaceutical
  • Novonordisk
  • Sanofi-Aventis
  • Servier
  • Bayer
  • Wanbang Biopharmaceuticals
  • GlaxoSmithKline
  • Guangzhou Pharmaceutical
  • Huadong Medicine
  • Pfizer

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Oral Hypoglycemic Agents (OHAs) Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Oral Hypoglycemic Agents (OHAs) Market Size Estimates and Forecasts (2021-2032)
  4. 1.4 Global Oral Hypoglycemic Agents (OHAs) Sales Estimates and Forecasts (2021-2032)
  5. 1.5 Global Oral Hypoglycemic Agents (OHAs) Market Average Price (2021-2032)
  6. 1.6 Assumptions and Limitations
  7. 1.7 Study Goals and Objectives
2 Global Oral Hypoglycemic Agents (OHAs) Market Dynamics
  1. 2.1 Oral Hypoglycemic Agents (OHAs) Industry Trends
  2. 2.2 Oral Hypoglycemic Agents (OHAs) Industry Drivers
  3. 2.3 Oral Hypoglycemic Agents (OHAs) Industry Opportunities and Challenges
  4. 2.4 Oral Hypoglycemic Agents (OHAs) Industry Restraints
3 Oral Hypoglycemic Agents (OHAs) Market by Manufacturers
  1. 3.1 Global Oral Hypoglycemic Agents (OHAs) Revenue by Manufacturers (2021-2026)
  2. 3.2 Global Oral Hypoglycemic Agents (OHAs) Sales by Manufacturers (2021-2026)
  3. 3.3 Global Oral Hypoglycemic Agents (OHAs) Average Sales Price by Manufacturers (2021-2026)
  4. 3.4 Global Oral Hypoglycemic Agents (OHAs) Industry Manufacturers Ranking, 2024 VS 2025 VS 2026
  5. 3.5 Global Oral Hypoglycemic Agents (OHAs) Key Manufacturers Manufacturing Sites & Headquarters
  6. 3.6 Global Oral Hypoglycemic Agents (OHAs) Manufacturers, Product Type & Application
  7. 3.7 Global Oral Hypoglycemic Agents (OHAs) Manufacturers Establishment Date
  8. 3.8 Market Competitive Analysis
  9. 3.8.1 Global Oral Hypoglycemic Agents (OHAs) Market CR5 and HHI
  10. 3.8.2 Global Top 5 and 10 Oral Hypoglycemic Agents (OHAs) Players Market Share by Revenue in 2025
  11. 3.8.3 2025 Oral Hypoglycemic Agents (OHAs) Tier 1, Tier 2, and Tier 3
4 Oral Hypoglycemic Agents (OHAs) Market by Type
  1. 4.1 Oral Hypoglycemic Agents (OHAs) Type Introduction
  2. 4.1.1 Alpha-Glucosidase Inhibitors
  3. 4.1.2 Metformin
  4. 4.1.3 Sulfonylureas
  5. 4.1.4 Thiazolidinediones
  6. 4.2 Global Oral Hypoglycemic Agents (OHAs) Sales by Type
  7. 4.2.1 Global Oral Hypoglycemic Agents (OHAs) Sales by Type (2021 VS 2025 VS 2032)
  8. 4.2.2 Global Oral Hypoglycemic Agents (OHAs) Sales by Type (2021-2032)
  9. 4.2.3 Global Oral Hypoglycemic Agents (OHAs) Sales Market Share by Type (2021-2032)
  10. 4.3 Global Oral Hypoglycemic Agents (OHAs) Revenue by Type
  11. 4.3.1 Global Oral Hypoglycemic Agents (OHAs) Revenue by Type (2021 VS 2025 VS 2032)
  12. 4.3.2 Global Oral Hypoglycemic Agents (OHAs) Revenue by Type (2021-2032)
  13. 4.3.3 Global Oral Hypoglycemic Agents (OHAs) Revenue Market Share by Type (2021-2032)
5 Oral Hypoglycemic Agents (OHAs) Market by Application
  1. 5.1 Oral Hypoglycemic Agents (OHAs) Application Introduction
  2. 5.1.1 Type 2 Diabetes Mellitus
  3. 5.1.2 Type 1 Diabetes Mellitus
  4. 5.2 Global Oral Hypoglycemic Agents (OHAs) Sales by Application
  5. 5.2.1 Global Oral Hypoglycemic Agents (OHAs) Sales by Application (2021 VS 2025 VS 2032)
  6. 5.2.2 Global Oral Hypoglycemic Agents (OHAs) Sales by Application (2021-2032)
  7. 5.2.3 Global Oral Hypoglycemic Agents (OHAs) Sales Market Share by Application (2021-2032)
  8. 5.3 Global Oral Hypoglycemic Agents (OHAs) Revenue by Application
  9. 5.3.1 Global Oral Hypoglycemic Agents (OHAs) Revenue by Application (2021 VS 2025 VS 2032)
  10. 5.3.2 Global Oral Hypoglycemic Agents (OHAs) Revenue by Application (2021-2032)
  11. 5.3.3 Global Oral Hypoglycemic Agents (OHAs) Revenue Market Share by Application (2021-2032)
6 Global Oral Hypoglycemic Agents (OHAs) Sales by Region
  1. 6.1 Global Oral Hypoglycemic Agents (OHAs) Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Oral Hypoglycemic Agents (OHAs) Sales by Region (2021-2032)
  3. 6.2.1 Global Oral Hypoglycemic Agents (OHAs) Sales by Region (2021-2026)
  4. 6.2.2 Global Oral Hypoglycemic Agents (OHAs) Sales Forecasted by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Oral Hypoglycemic Agents (OHAs) Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  7. 6.3.2 North America Oral Hypoglycemic Agents (OHAs) Sales by Country (2021-2032)
  8. 6.3.3 U.S.
  9. 6.3.4 Canada
  10. 6.3.5 Mexico
  11. 6.4 Europe
  12. 6.4.1 Europe Oral Hypoglycemic Agents (OHAs) Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  13. 6.4.2 Europe Oral Hypoglycemic Agents (OHAs) Sales by Country (2021-2032)
  14. 6.4.3 Germany
  15. 6.4.4 France
  16. 6.4.5 U.K.
  17. 6.4.6 Italy
  18. 6.4.7 Netherlands
  19. 6.5 Asia Pacific
  20. 6.5.1 Asia Pacific Oral Hypoglycemic Agents (OHAs) Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  21. 6.5.2 Asia Pacific Oral Hypoglycemic Agents (OHAs) Sales by Country (2021-2032)
  22. 6.5.3 China
  23. 6.5.4 Japan
  24. 6.5.5 South Korea
  25. 6.5.6 Southeast Asia
  26. 6.5.7 India
  27. 6.5.8 Australia
  28. 6.6 South America, Middle East and Africa
  29. 6.6.1 South America, Middle East and Africa Oral Hypoglycemic Agents (OHAs) Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  30. 6.6.2 South America, Middle East and Africa Oral Hypoglycemic Agents (OHAs) Sales by Country (2021-2032)
  31. 6.6.3 Brazil
  32. 6.6.4 South Africa
  33. 6.6.5 Saudi Arabia
  34. 6.6.6 Turkey
  35. 6.6.6 Argentina
  36. 6.6.6 UAE
  37. 6.6.6 Egypt
  38. 6.6.6 Chile
7 Global Oral Hypoglycemic Agents (OHAs) Revenue by Region
  1. 7.1 Global Oral Hypoglycemic Agents (OHAs) Revenue by Region
  2. 7.1.1 Global Oral Hypoglycemic Agents (OHAs) Revenue by Region: 2021 VS 2025 VS 2032
  3. 7.1.2 Global Oral Hypoglycemic Agents (OHAs) Revenue by Region (2021-2026)
  4. 7.1.3 Global Oral Hypoglycemic Agents (OHAs) Revenue by Region (2027-2032)
  5. 7.1.4 Global Oral Hypoglycemic Agents (OHAs) Revenue Market Share by Region (2021-2032)
  6. 7.2 North America
  7. 7.2.1 North America Oral Hypoglycemic Agents (OHAs) Revenue (2021-2032)
  8. 7.2.2 North America Oral Hypoglycemic Agents (OHAs) Revenue Share by Country: 2021 VS 2025 VS 2032
  9. 7.3 Europe
  10. 7.3.1 Europe Oral Hypoglycemic Agents (OHAs) Revenue (2021-2032)
  11. 7.3.2 Europe Oral Hypoglycemic Agents (OHAs) Revenue Share by Country: 2021 VS 2025 VS 2032
  12. 7.4 Asia-Pacific
  13. 7.4.1 Asia-Pacific Oral Hypoglycemic Agents (OHAs) Revenue (2021-2032)
  14. 7.4.2 Asia-Pacific Oral Hypoglycemic Agents (OHAs) Revenue Share by Country: 2021 VS 2025 VS 2032
  15. 7.5 South America, Middle East and Africa
  16. 7.5.1 South America, Middle East and Africa Oral Hypoglycemic Agents (OHAs) Revenue (2021-2032)
  17. 7.5.2 South America, Middle East and Africa Oral Hypoglycemic Agents (OHAs) Revenue Share by Country: 2021 VS 2025 VS 2032
8 Company Profiles
  1. 8.1 Bristol-Myers Squibb
  2. 8.1.1 Bristol-Myers Squibb Company Information
  3. 8.1.2 Bristol-Myers Squibb Business Overview
  4. 8.1.3 Bristol-Myers Squibb Oral Hypoglycemic Agents (OHAs) Sales, Price, Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Bristol-Myers Squibb Oral Hypoglycemic Agents (OHAs) Product Portfolio
  6. 8.1.5 Bristol-Myers Squibb Recent Developments
  7. 8.2 Double-Crane Pharmaceutical
  8. 8.2.1 Double-Crane Pharmaceutical Company Information
  9. 8.2.2 Double-Crane Pharmaceutical Business Overview
  10. 8.2.3 Double-Crane Pharmaceutical Oral Hypoglycemic Agents (OHAs) Sales, Price, Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Double-Crane Pharmaceutical Oral Hypoglycemic Agents (OHAs) Product Portfolio
  12. 8.2.5 Double-Crane Pharmaceutical Recent Developments
  13. 8.3 Novonordisk
  14. 8.3.1 Novonordisk Company Information
  15. 8.3.2 Novonordisk Business Overview
  16. 8.3.3 Novonordisk Oral Hypoglycemic Agents (OHAs) Sales, Price, Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Novonordisk Oral Hypoglycemic Agents (OHAs) Product Portfolio
  18. 8.3.5 Novonordisk Recent Developments
  19. 8.4 Sanofi-Aventis
  20. 8.4.1 Sanofi-Aventis Company Information
  21. 8.4.2 Sanofi-Aventis Business Overview
  22. 8.4.3 Sanofi-Aventis Oral Hypoglycemic Agents (OHAs) Sales, Price, Revenue and Gross Margin (2021-2026)
  23. 8.4.4 Sanofi-Aventis Oral Hypoglycemic Agents (OHAs) Product Portfolio
  24. 8.4.5 Sanofi-Aventis Recent Developments
  25. 8.5 Servier
  26. 8.5.1 Servier Company Information
  27. 8.5.2 Servier Business Overview
  28. 8.5.3 Servier Oral Hypoglycemic Agents (OHAs) Sales, Price, Revenue and Gross Margin (2021-2026)
  29. 8.5.4 Servier Oral Hypoglycemic Agents (OHAs) Product Portfolio
  30. 8.5.5 Servier Recent Developments
  31. 8.6 Bayer
  32. 8.6.1 Bayer Company Information
  33. 8.6.2 Bayer Business Overview
  34. 8.6.3 Bayer Oral Hypoglycemic Agents (OHAs) Sales, Price, Revenue and Gross Margin (2021-2026)
  35. 8.6.4 Bayer Oral Hypoglycemic Agents (OHAs) Product Portfolio
  36. 8.6.5 Bayer Recent Developments
  37. 8.7 Wanbang Biopharmaceuticals
  38. 8.7.1 Wanbang Biopharmaceuticals Company Information
  39. 8.7.2 Wanbang Biopharmaceuticals Business Overview
  40. 8.7.3 Wanbang Biopharmaceuticals Oral Hypoglycemic Agents (OHAs) Sales, Price, Revenue and Gross Margin (2021-2026)
  41. 8.7.4 Wanbang Biopharmaceuticals Oral Hypoglycemic Agents (OHAs) Product Portfolio
  42. 8.7.5 Wanbang Biopharmaceuticals Recent Developments
  43. 8.8 GlaxoSmithKline
  44. 8.8.1 GlaxoSmithKline Company Information
  45. 8.8.2 GlaxoSmithKline Business Overview
  46. 8.8.3 GlaxoSmithKline Oral Hypoglycemic Agents (OHAs) Sales, Price, Revenue and Gross Margin (2021-2026)
  47. 8.8.4 GlaxoSmithKline Oral Hypoglycemic Agents (OHAs) Product Portfolio
  48. 8.8.5 GlaxoSmithKline Recent Developments
  49. 8.9 Guangzhou Pharmaceutical
  50. 8.9.1 Guangzhou Pharmaceutical Company Information
  51. 8.9.2 Guangzhou Pharmaceutical Business Overview
  52. 8.9.3 Guangzhou Pharmaceutical Oral Hypoglycemic Agents (OHAs) Sales, Price, Revenue and Gross Margin (2021-2026)
  53. 8.9.4 Guangzhou Pharmaceutical Oral Hypoglycemic Agents (OHAs) Product Portfolio
  54. 8.9.5 Guangzhou Pharmaceutical Recent Developments
  55. 8.10 Huadong Medicine
  56. 8.10.1 Huadong Medicine Company Information
  57. 8.10.2 Huadong Medicine Business Overview
  58. 8.10.3 Huadong Medicine Oral Hypoglycemic Agents (OHAs) Sales, Price, Revenue and Gross Margin (2021-2026)
  59. 8.10.4 Huadong Medicine Oral Hypoglycemic Agents (OHAs) Product Portfolio
  60. 8.10.5 Huadong Medicine Recent Developments
  61. 8.11 Pfizer
  62. 8.11.1 Pfizer Company Information
  63. 8.11.2 Pfizer Business Overview
  64. 8.11.3 Pfizer Oral Hypoglycemic Agents (OHAs) Sales, Price, Revenue and Gross Margin (2021-2026)
  65. 8.11.4 Pfizer Oral Hypoglycemic Agents (OHAs) Product Portfolio
  66. 8.11.5 Pfizer Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Oral Hypoglycemic Agents (OHAs) Value Chain Analysis
  2. 9.1.1 Oral Hypoglycemic Agents (OHAs) Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Oral Hypoglycemic Agents (OHAs) Production Mode & Process
  6. 9.2 Oral Hypoglycemic Agents (OHAs) Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Oral Hypoglycemic Agents (OHAs) Distributors
  9. 9.2.3 Oral Hypoglycemic Agents (OHAs) Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources
    8. 11.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst